Headlines about Celldex Therapeutics (NASDAQ:CLDX) have trended somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Celldex Therapeutics earned a coverage optimism score of 0.23 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 46.6483959726705 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the news articles that may have effected Accern’s analysis:
- Notable Investor’s Alert – Deutsche Bank Aktiengesellschaft, NYSE: DB), Celldex Therapeutics, Inc., (NASDAQ: CLDX) (dailynysenews.com)
- Celldex Therapeutics, Inc. (CLDX) Reached 52 Week Low on Apr, 6 (thecasualsmart.com)
- $2.03 Million in Sales Expected for Celldex Therapeutics, Inc. (CLDX) This Quarter (americanbankingnews.com)
- Financial Survey: Oxford Immunotec Global (OXFD) & Celldex Therapeutics (CLDX) (americanbankingnews.com)
- Celldex Therapeutics, Inc. (CLDX) Expected to Post Earnings of -$0.17 Per Share (americanbankingnews.com)
CLDX has been the topic of a number of research analyst reports. BidaskClub upgraded Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, January 5th. HC Wainwright set a $10.00 price objective on Celldex Therapeutics and gave the company a “buy” rating in a research report on Friday, February 9th. Cantor Fitzgerald restated a “buy” rating and set a $9.00 price objective on shares of Celldex Therapeutics in a research report on Wednesday, March 7th. Finally, Leerink Swann restated a “market perform” rating and set a $3.00 price objective (down from $4.00) on shares of Celldex Therapeutics in a research report on Thursday, March 8th. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $6.38.
Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings data on Wednesday, March 7th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.08. Celldex Therapeutics had a negative return on equity of 44.64% and a negative net margin of 730.06%. The business had revenue of $3.50 million for the quarter, compared to the consensus estimate of $1.49 million. During the same period in the prior year, the business posted ($0.30) earnings per share. The company’s quarterly revenue was up 87.2% compared to the same quarter last year. equities research analysts predict that Celldex Therapeutics will post -0.72 EPS for the current year.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer; and CDX-3379, a human monoclonal antibody that is in Phase II study in combination with cetuximab for the treatment of head and neck squamous cell carcinoma.
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.